Recent INKT News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:02:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:30:18 AM
- MiNK Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 11:28:28 AM
- MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer • GlobeNewswire Inc. • 05/13/2024 11:30:00 AM
- MiNK to Provide Corporate Update and First Quarter 2024 Financial Report • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR • GlobeNewswire Inc. • 04/08/2024 04:00:00 PM
- U.S. Index Futures Rise as Fed’s Dovish Outlook Spurs Positive Investor Sentiment; Oil Prices See Minor Declines • IH Market News • 03/21/2024 11:26:38 AM
- MiNK Reports Fourth Quarter and Year-End 2023 Results • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report • GlobeNewswire Inc. • 03/07/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 01:00:11 PM
- First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab • GlobeNewswire Inc. • 02/14/2024 01:00:00 PM
- MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 01:00:08 AM
- ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development • GlobeNewswire Inc. • 12/20/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 11:05:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:00:23 PM
- MiNK Therapeutics Reports Third Quarter 2023 Results • GlobeNewswire Inc. • 11/09/2023 12:00:00 PM
- MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023 • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update • GlobeNewswire Inc. • 10/30/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 08:15:08 PM
- MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023 • GlobeNewswire Inc. • 09/27/2023 01:05:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • May 16, 2024 8:13 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM